HALO Valuation

Halozyme Therapeutics Inc

Add to Watchlist

Advanced Chart

57.930

-0.31(-0.532%)1D

Overview
Forecast
Valuation
Earnings

HALO Relative Valuation

HALO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HALO is overvalued; if below, it's undervalued.

Historical Valuation

Halozyme Therapeutics Inc (HALO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 10.11 is considered Undervalued compared with the five-year average of 15.65. The fair price of Halozyme Therapeutics Inc (HALO) is between 77.71 to 121.40 according to relative valuation methord. Compared to the current price of 58.24 USD , Halozyme Therapeutics Inc is Undervalued By 25.05%.

Relative Value

Fair Zone

77.71-121.40

Current Price：58.24

25.05%

Undervalued

10.11

Trailing

Forward

9.21

EV/EBITDA

Halozyme Therapeutics Inc. (HALO) has a current EV/EBITDA of 9.21. The 5-year average EV/EBITDA is 14.55. The thresholds are as follows: Strongly Undervalued below 6.16, Undervalued between 6.16 and 10.35, Fairly Valued between 18.74 and 10.35, Overvalued between 18.74 and 22.93, and Strongly Overvalued above 22.93. The current Forward EV/EBITDA of 9.21 falls within the Undervalued range.

9.78

EV/EBIT

Halozyme Therapeutics Inc. (HALO) has a current EV/EBIT of 9.78. The 5-year average EV/EBIT is 16.17. The thresholds are as follows: Strongly Undervalued below 7.11, Undervalued between 7.11 and 11.64, Fairly Valued between 20.70 and 11.64, Overvalued between 20.70 and 25.23, and Strongly Overvalued above 25.23. The current Forward EV/EBIT of 9.78 falls within the Undervalued range.

5.41

Halozyme Therapeutics Inc. (HALO) has a current PS of 5.41. The 5-year average PS is 8.12. The thresholds are as follows: Strongly Undervalued below 1.86, Undervalued between 1.86 and 4.99, Fairly Valued between 11.24 and 4.99, Overvalued between 11.24 and 14.37, and Strongly Overvalued above 14.37. The current Forward PS of 5.41 falls within the Historic Trend Line -Fairly Valued range.

9.32

P/OCF

Halozyme Therapeutics Inc. (HALO) has a current P/OCF of 9.32. The 5-year average P/OCF is 16.89. The thresholds are as follows: Strongly Undervalued below 4.39, Undervalued between 4.39 and 10.64, Fairly Valued between 23.14 and 10.64, Overvalued between 23.14 and 29.39, and Strongly Overvalued above 29.39. The current Forward P/OCF of 9.32 falls within the Undervalued range.

9.40

P/FCF

Halozyme Therapeutics Inc. (HALO) has a current P/FCF of 9.40. The 5-year average P/FCF is 16.31. The thresholds are as follows: Strongly Undervalued below 5.87, Undervalued between 5.87 and 11.09, Fairly Valued between 21.53 and 11.09, Overvalued between 21.53 and 26.75, and Strongly Overvalued above 26.75. The current Forward P/FCF of 9.40 falls within the Undervalued range.

Halozyme Therapeutics Inc (HALO) has a current Price-to-Book (P/B) ratio of 14.87. Compared to its 3-year average P/B ratio of 34.78 , the current P/B ratio is approximately -57.23% higher. Relative to its 5-year average P/B ratio of 37.47, the current P/B ratio is about -60.31% higher. Halozyme Therapeutics Inc (HALO) has a Forward Free Cash Flow (FCF) yield of approximately 6.91%. Compared to its 3-year average FCF yield of 5.91%, the current FCF yield is approximately 16.81% lower. Relative to its 5-year average FCF yield of 4.57% , the current FCF yield is about 51.21% lower.

14.87

P/B

Median3y

34.78

Median5y

37.47

6.91

FCF Yield

Median3y

5.91

Median5y

4.57

Competitors Valuation Multiple

The average P/S ratio for HALO's competitors is 23.30, providing a benchmark for relative valuation. Halozyme Therapeutics Inc Corp (HALO) exhibits a P/S ratio of 5.41, which is -76.80% above the industry average. Given its robust revenue growth of 35.22%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

HALO.O

Halozyme Therapeutics Inc

Telix Pharmaceuticals Ltd

6.03

9.61B

ELAN.N

Elanco Animal Health Inc

CRISPR Therapeutics AG

Performance Decomposition

Market capitalization of HALO increased by 5.39% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 195.88M to 264.86M.

The secondary factor is the Margin Expansion, contributed 13.69%to the performance.

Overall, the performance of HALO in the past 1 year is driven by Revenue Growth. Which is more sustainable.

35.22%

195.88M → 264.86M

Revenue Growth

13.69%

39.22 → 44.59

Margin Expansion

-43.52%

27.43 → 15.49

P/E Change

5.39%